Biofluid-based Biomarkers in Traumatic Brain Injury: A Narrative Review
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Traumatic brain injury (TBI) is a complex condition characterized by a multifaceted pathophysiology. It presents significant diagnostic and prognostic challenges in clinical settings. This narrative review explores the evolving role of biofluid biomarkers as essential tools in the diagnosis, prognosis, and treatment of TBI. In recent times, preclinical and clinical trials utilizing these biofluid biomarkers have been actively pursued internationally. Among the biomarkers for nerve tissue proteins are neuronal biomarkers like neuronal specific enolase and ubiquitin C-terminal hydrolase L1; astroglia injury biomarkers such as S100B and glial fibrillary acidic protein; axonal injury and demyelination biomarkers, including neurofilaments and myelin basic protein; new axonal injury and neurodegeneration biomarkers like total tau and phosphorylated tau; and others such as spectrin breakdown products and microtubule-associated protein 2. The interpretation of these biomarkers can be influenced by various factors, including secretion from organs other than the injury site and systemic conditions. This review highlights the potential of these biomarkers to transform TBI management and emphasizes the need for continued research to validate their efficacy, refine testing platforms, and ultimately improve patient care and outcomes.
Abstract
Traumatic brain injury (TBI) is a complex condition characterized by a multifaceted pathophysiology. It presents significant diagnostic and prognostic challenges in clinical settings. This narrative review explores the evolving role of biofluid biomarkers as essential tools in the diagnosis, prognosis, and treatment of TBI. In recent times, preclinical and clinical trials utilizing these biofluid biomarkers have been actively pursued internationally. Among the biomarkers for nerve tissue proteins are neuronal biomarkers like neuronal specific enolase and ubiquitin C-terminal hydrolase L1; astroglia injury biomarkers such as S100B and glial fibrillary acidic protein; axonal injury and demyelination biomarkers, including neurofilaments and myelin basic protein; new axonal injury and neurodegeneration biomarkers like total tau and phosphorylated tau; and others such as spectrin breakdown products and microtubule-associated protein 2. The interpretation of these biomarkers can be influenced by various factors, including secretion from organs other than the injury site and systemic conditions. This review highlights the potential of these biomarkers to transform TBI management and emphasizes the need for continued research to validate their efficacy, refine testing platforms, and ultimately improve patient care and outcomes.
참고문헌 (53)
- Dadas A, "Biomarkers in traumatic brain injury(TBI) : a review", Neuropsychiatr Dis Treat, 14, pp.2989~3000 (2018)
- Wang KK, "An update on diagnostic and prognostic biomarkers for traumatic brain injury", Expert Rev Mol Diagn, 18, pp.165~180 (2018)
- Lewczuk P, "Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias : an update of the consensus of the task force on biological markers in psychiatry of the World Federation of Societies of Biological Psychiatry", World J Biol Psychiatry, 19, pp.244~328 (2018)
- Kamtchum-Tatuene J, "Blood biomarkers for stroke diagnosis and management", Neuromolecular Med, 21, pp.344~368 (2019)
- Ehrenberg AJ, "Relevance of biomarkers across different neurodegenerative diseases", Alzheimers Res Ther, 12, pp.56~ (2020)
- Sturmey E, "Blood biomarkers in ALS : challenges, applications and novel frontiers", Acta Neurol Scand, 146, pp.375~388 (2022)
- Yang J, "Current and future biomarkers in multiple sclerosis", Int J Mol Sci, 23, pp.5877~ (2022)
- McGinn MJ, "Pathophysiology of traumatic brain injury", Neurosurg Clin N Am, 27, pp.397~407 (2016)
- Dixon KJ, "Pathophysiology of traumatic brain injury", Phys Med Rehabil Clin N Am, 28, pp.215~225 (2017)
- Pearn ML, "Pathophysiology associated with traumatic brain injury : current treatments and potential novel therapeutics", Cell Mol Neurobiol, 37, pp.571~585 (2017)
- Andriessen TM, "Epidemiology, severity classification, and outcome of moderate and severe traumatic brain injury : a prospective multicenter study", J Neurotrauma, 28, pp.2019~2031 (2011)
- Joseph B, "Mild traumatic brain injury defined by Glasgow Coma Scale : is it really mild?", Brain Inj, 29, pp.11~16 (2015)
- Geeraerts T, "Management of severe traumatic brain injury(first 24hours)", Anaesth Crit Care Pain Med, 37, pp.171~186 (2018)
- Melnick ER, "CT overuse for mild traumatic brain injury", Jt Comm J Qual Patient Saf, 38, pp.483~489 (2012)
- Nagesh M, "Role of repeat CT in mild to moderate head injury : an institutional study", Neurosurg Focus, 47, pp.E2~ (2019)
- Jarrahi A, "Revisiting traumatic brain injury : from molecular mechanisms to therapeutic interventions", Biomedicines, 8, pp.389~ (2020)
- Edalatfar M, "Biofluid biomarkers in traumatic brain injury : a systematic scoping review", Neurocrit Care, 35, pp.559~572 (2021)
- Kövesdi E, "Update on protein biomarkers in traumatic brain injury with emphasis on clinical use in adults and pediatrics", Acta Neurochir(Wien), 152, pp.1~17 (2010)
- Isgrò MA, "Neuron-specific enolase as a biomarker : biochemical and clinical aspects", Adv Exp Med Biol, 867, pp.125~143 (2015)
- Papa L, "Systematic review of clinical research on biomarkers for pediatric traumatic brain injury", J Neurotrauma, 30, pp.324~338 (2013)
- Neher MD, "Serum biomarkers for traumatic brain injury", South Med J, 107, pp.248~255 (2014)
- Thelin EP, "Serial sampling of serum protein biomarkers for monitoring human traumatic brain injury dynamics : a systematic review", Front Neurol, 8, pp.300~ (2017)
- Mondello S, "Blood-based protein biomarkers for the management of traumatic brain injuries in adults presenting to emergency departments with mild brain injury : a living systematic review and meta-analysis", J Neurotrauma, 38, pp.1086~1106 (2021)
- Toman E, "Biomarkers in traumatic brain injury : a review", J R Army Med Corps, 162, pp.103~108 (2016)
- Mehta T, "Current trends in biomarkers for traumatic brain injury", Open Access J Neurol Neurosurg, 12, pp.86~94 (2020)
- Mondello S, "Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury", Neurosurgery, 70, pp.666~675 (2012)
- Papa L, "Serum levels of ubiquitin C-terminal hydrolase distinguish mild traumatic brain injury from trauma controls and are elevated in mild and moderate traumatic brain injury patients with intracranial lesions and neurosurgical intervention", J Trauma Acute Care Surg, 72, pp.1335~1344 (2012)
- Mercier E, "Predictive value of S-100β protein for prognosis in patients with moderate and severe traumatic brain injury : systematic review and meta-analysis", BMJ, 346, pp.f1757~ (2013)
- Oris C, "The biomarker S100B and mild traumatic brain injury : a meta-analysis", Pediatrics, 141, pp.e20180037~ (2018)
- Undén L, "Validation of the Scandinavian guidelines for initial management of minimal, mild and moderate traumatic brain injury in adults", BMC Med, 13, pp.292~ (2015)
- Mercier E, "Prognostic value of S-100β protein for prediction of post-concussion symptoms after a mild traumatic brain injury : systematic review and meta-analysis", J Neurotrauma, 35, pp.609~622 (2018)
- Okonkwo DO, "Point-of-care platform blood biomarker testing of glial fibrillary acidic protein versus S100 calcium-binding protein b for prediction of traumatic brain injuries : a transforming research and clinical knowledge in traumatic brain injury study", J Neurotrauma, 37, pp.2460~2467 (2020)
- Yue JK, "Association between plasma GFAP concentrations and MRI abnormalities in patients with CT-negative traumatic brain injury in the TRACK-TBI cohort : a prospective multicentre study", Lancet Neurol, 18, pp.953~961 (2019)
- Lei J, "Glial fibrillary acidic protein as a biomarker in severe traumatic brain injury patients : a prospective cohort study", Crit Care, 19, pp.362~ (2015)
- Mondello S, "Serum concentrations of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein after pediatric traumatic brain injury", Sci Rep, 6, pp.28203~ (2016)
- Papa L, "Time course and diagnostic accuracy of glial and neuronal blood biomarkers GFAP and UCH-L1 in a large cohort of trauma patients with and without mild traumatic brain injury", JAMA Neurol, 73, pp.551~560 (2016)
- Posti JP, "The levels of glial fibrillary acidic protein and ubiquitin C-terminal hydrolase-L1 during the first week after a traumatic brain injury : correlations with clinical and imaging findings", Neurosurgery, 79, pp.456~464 (2016)
- Bazarian JJ, "Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT(ALERT-TBI) : a multicentre observational study", Lancet Neurol, 17, pp.782~789 (2018)
- Anderson KJ, "The phosphorylated axonal form of the neurofilament subunit NF-H(pNF-H)as a blood biomarker of traumatic brain injury", J Neurotrauma, 25, pp.1079~1085 (2008)
- Neselius S, "Increased CSF levels of phosphorylated neurofilament heavy protein following bout in amateur boxers", PLoS One, 8, pp.e81249~ (2013)
- Al Nimer F, "Comparative assessment of the prognostic value of biomarkers in traumatic brain injury reveals an independent role for serum levels of neurofilament light", PLoS One, 10, pp.e0132177~ (2015)
- Martínez-Morillo E, "Neurofilament medium polypeptide(NFM)protein concentration is increased in CSF and serum samples from patients with brain injury", Clin Chem Lab Med, 53, pp.1575~1584 (2015)
- Liu MC, "Extensive degradation of myelin basic protein isoforms by calpain following traumatic brain injury", J Neurochem, 98, pp.700~712 (2006)
- Ottens AK, "Proteolysis of multiple myelin basic protein isoforms after neurotrauma : characterization by mass spectrometry", J Neurochem, 104, pp.1404~1414 (2008)
- Ringger NC, "A novel marker for traumatic brain injury : CSF alphaII-spectrin breakdown product levels", J Neurotrauma, 21, pp.1443~1456 (2004)
- Zhang Z, "Biomarkers of brain injury and neurological disorders", pp.134~153 (2014), CRC Press
- Rubenstein R, "A novel, ultrasensitive assay for tau : potential for assessing traumatic brain injury in tissues and biofluids", J Neurotrauma, 32, pp.342~352 (2015)
- Olivera A, "Peripheral total tau in military personnel who sustain traumatic brain injuries during deployment", JAMA Neurol, 72, pp.1109~1116 (2015)
- Mayeux R, "Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer’s disease", Neurology, 45, pp.555~557 (1995)
- Zeiler FA, "Cerebrospinal fluid and microdialysis cytokines in severe traumatic brain injury : a scoping systematic review", Front Neurol, 8, pp.331~ (2017)
- Rodney T, "Pro-and anti-inflammatory biomarkers and traumatic brain injury outcomes : a review", Cytokine, 110, pp.248~256 (2018)
- Lagerstedt L, "Early measurement of interleukin-10 predicts the absence of CT scan lesions in mild traumatic brain injury", PLoS One, 13, pp.e0193278~ (2018)
- Woodcock T, "The role of markers of inflammation in traumatic brain injury", Front Neurol, 4, pp.18~ (2013)
